Project Grant R01AG088141
- The University of Missouri System was awarded a $392,026 Project Grant from the National Institute on Aging (CFDA 93.866 - Aging Research) to develop an innovative approach for treating Alzheimer's disease (AD). The key product being delivered is a novel therapeutic intervention that aims to systematically and sustainably elevate nicotinamide adenine dinucleotide (NAD+) levels in the body to counteract NAD+ decline associated with AD progression. The project will utilize a helper-dependent...
- This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $1,257,163 to the Icahn School of Medicine at Mount Sinai to develop a humanized monoclonal antibody targeting follicle-stimulating hormone (FSH) as a potential treatment for Alzheimer's disease in individuals with Down syndrome. The 5-year project, beginning on Jul 1, 2025, will first measure FSH levels across the lifespan in mouse models of Down syndrome...
- This federal Project Grant award of $238,500 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support research conducted by the University of California, San Diego (UCSD) to develop a new phosphorodiamidate morpholino oligonucleotide (PMO) therapeutic for treating Alzheimer's disease (AD). The research aims to create a highly effective PMO that can...
- This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $2,357,335 to study neuronal dysfunction in Down syndrome (DS) and its link to Alzheimer's disease (AD). The key products and services delivered under this award include: Utilizing induced pluripotent stem cell (iPSC)-derived cortical organoids and assembloids to examine the cellular, transcriptomic, and motility-related...
- This Project Grant award of $1,346,873 from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) is supporting research to establish an Alzheimer's disease biomarker clock in individuals with Down syndrome. The project aims to utilize positron emission tomography (PET) imaging and plasma analytes to longitudinally assess changes in amyloid, tau, and neurodegeneration biomarkers prior to the onset of dementia in this population. This research will address key...
- This Project Grant award from the Department of Health and Human Services' National Institutes of Health (CFDA 93.310 - Trans-NIH Research Support) will provide $1,257,163.00 to the Icahn School of Medicine at Mount Sinai to develop a humanized monoclonal antibody targeting follicle-stimulating hormone (FSH) for treating Alzheimer's disease and associated health conditions in individuals with Down syndrome. The project aims to first measure FSH levels across the lifespan in mouse models of...
- This Project Grant award, funded by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310), is focused on investigating the susceptibility of basal forebrain cholinergic neurons in individuals with Down syndrome. The key objectives of this $111,783 award, which runs from November 9, 2024 to June 30, 2026, are to: 1) determine if there are fewer basal forebrain cholinergic neurons and earlier accumulation of Alzheimer's disease pathology in the early...
- This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $2,173,794 to The General Hospital Corporation (Massachusetts General Hospital) to conduct research on enhancing brain resilience to Alzheimer's disease by targeting adult hippocampal neurogenesis. The project aims to explore the mechanisms by which adult hippocampal neurogenesis cooperates with brain-derived neurotrophic factor (BDNF) to potentially slow cognitive decline in...
- The U.S. Department of Health and Human Services, National Institutes of Health (NIH) awarded a $1,017,548 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to the University of North Carolina at Chapel Hill. The grant, titled "HOME GROWN: A FAMILY-BASED LIFESTYLE INTERVENTION TO SUPPORT HEALTHY DEVELOPMENT OF YOUNG CHILDREN WITH DOWN SYNDROME," will fund a 2-phase study to evaluate the feasibility (R61 phase) and efficacy (R33 phase) of a tailored healthy...
- This Project Grant award, with a total funding amount of $878,190.00, was provided by the National Institute on Aging (part of the U.S. Department of Health and Human Services) under the Aging Research federal grant program (CFDA 93.866). The grant is supporting research by the Scripps Research Institute in California to investigate a "druggable mito-nuclear feedback mechanism" that can preserve mitochondrial and synaptic function in aging and age-related dementias like Alzheimer's...
This Project Grant award, totaling $801,359.00 and provided by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310), will fund a multiple ascending dose, placebo-controlled Phase 1 clinical trial to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of nicotinamide mononucleotide (NMN) in adults with Down syndrome. The goal is to evaluate NMN as a potential therapeutic to prevent or slow the progression of Alzheimer's disease in this population, as NMN has shown promise in reducing Alzheimer's-related neuropathology through multiple mechanisms. The award was granted to Brigham & Women's Hospital Inc., a subsidiary of the larger Partners Healthcare System, which has extensive expertise in federal research grants across various biomedical and health-related domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $801.4k | 9/8/25 |